Immunological Biomarkers
(Certainty: 0.50 — MDSC flow cytometry is established in oncology; the question is whether the HSAT2-loop mechanism is operative in ME/CFS.)
If the exosomal HSAT2 loop drives MDSC expansion in ME/CFS:mdsc-nk-bridge, then CD33+HLA-DR− cell frequency in peripheral blood is a direct readout of the loop’s activity. This cell population:
- Is routinely measurable by flow cytometry with standard panels
- Is already used as a biomarker in oncology immunotherapy monitoring
- Would be expected to correlate inversely with NK cytotoxicity — the most replicated ME/CFS finding
- Could serve as an eligibility criterion and pharmacodynamic endpoint for HSAT2-targeted interventions
Evidence gap — no ME/CFS MDSC data: No published immunophenotyping study in ME/CFS has measured MDSCs. The 2024 NIH deep-phenotyping study (Walitt et al., Nature Communications), the 2024 Frontiers in Immunology ME/CFS biology review, and all other ME/CFS immune studies found through systematic search do not report MDSC quantification. Whether MDSC frequencies are elevated, normal, or reduced in ME/CFS is currently unknown. This is the most critical gap for this hypothesis.
Proxy populations in order of relevance: Post-COVID at 5 months (BeliakovanBethell 2022, already in bib): M-MDSC 0.9 ± 0.2% vs 0.2 ± 0.09% in uninfected controls — the most temporally analogous proxy, indicating persistent immunosuppression after viral resolution. Chronic HCV MDSC expansion (Goh 2016, already in bib): establishes the pattern in a chronic viral disease without spontaneous resolution. SLE patients: CD14+HLA-DR−/low M-MDSC significantly elevated versus controls, correlating with disease activity score SLEDAI (r = 0.547, p < 0.01) and iNOS-dependent suppression mechanism These proxies support the plausibility of persistent MDSC elevation in chronic post-viral immune states, but cross-disease extrapolation is uncertain.
Healthy adult reference range: M-MDSC (CD14+HLA-DR−/lo): approximately 0.2–0.5% of PBMCs in healthy adults. Reference ranges are sex- and age-stratified; younger and female individuals have slightly higher frequencies
Standardization requirements for multi-site studies: The current best standardization framework is the EuroFlow 2022 Salminen et al. protocol (Frontiers in Immunology 2022): a validated 11-color and 14-color panel for innate myeloid cells with a 4-hour processing window, EDTA and heparin both acceptable, inter-center CV ~5%, and age/sex-stratified reference ranges from 116 healthy donors. CD33 gating is the primary source of inter-lab variability; fluorescence-minus-one (FMO) controls or an internal monocyte-negative gate are required for HLA-DR threshold setting PBMC preparation by density gradient loses PMN-MDSCs (co-separated with red blood cells); whole blood assays are preferred when PMN-MDSC quantification is needed. Four-hour processing window from venipuncture is the standard.
Falsifiable prediction: CD33+HLA-DR− MDSC frequency will be elevated > 1.5× in ≥ 30% of ME/CFS patients versus matched healthy controls; MDSC frequency will correlate inversely with NK cytotoxicity in the same sample (Spearman ρ < −0.4). If MDSC frequency is normal in ME/CFS blood, the MDSC-bridge model is not operative.
Limitations: No ME/CFS MDSC data exists; the hypothesis is entirely proxy-based. MDSC quantification is technically sensitive to sample handling, processing time, and gating strategy — the 4-hour processing window must be maintained and FMO controls included in every run. Whether ME/CFS MDSCs carry HSAT2 RNA (as in Evdokimova’s Ewing sarcoma EVs) would need to be confirmed with PrimeFlow RNA assay or equivalent in-situ method. The iNOS-dependent suppression mechanism documented in SLE may differ from the arginase/ROS mechanism reported in post-COVID contexts — ME/CFS suppression mechanism is entirely unknown. Replication status: not replicated (no ME/CFS data).
1 Cytokine Profiles
1.1 Studies Identifying Cytokine Patterns
Numerous studies have examined cytokines in ME/CFS:
- Early illness: More consistent elevation of pro-inflammatory cytokines
- Chronic illness: More variable, often normalized
- Specific cytokines: IL-1, IL-6, TNF-\(\alpha\), IFN-\(\gamma\) variably elevated
- Cytokine networks: Pattern analysis may be more informative than individual cytokines
1.2 Variability and Consistency
Challenges in cytokine research:
- Different assays with different sensitivities
- Timing of blood draw (diurnal variation)
- Recent activity effects
- Heterogeneous patient populations
1.3 Correlation with Symptoms
When correlations are found:
- Higher cytokines often correlate with greater severity
- Cytokine patterns may predict symptom clusters
- Post-exertional changes in cytokines documented
1.4 CCL2 (MCP-1) and Symptom Severity
Montoya et al. (2017, \(n = 192\)) identified CCL2 (monocyte chemoattractant protein-1) among the cytokines most strongly correlating with ME/CFS symptom severity CCL2 drives monocyte and T-cell recruitment and reflects ongoing innate immune activation; its severity correlation makes it one of the stronger candidate immunological biomarkers from the cytokine literature.
1.5 Neopterin: Macrophage Activation Marker
Neopterin, a pteridine produced by macrophages in response to IFN-\(\gamma\) stimulation, has been reported elevated in ME/CFS cohorts As a non-specific marker of IFN-\(\gamma\)-driven macrophage activation, elevated neopterin is consistent with the type-I/II interferon evidence base in ME/CFS, though it has not been validated as a diagnostic marker.
1.6 CRP and ESR: Diagnostically Informative Normal Findings
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are typically normal in ME/CFS despite significant symptom burden. This normal finding is itself diagnostically important: it distinguishes ME/CFS from active inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, and active infection, all of which produce CRP and ESR elevation. Clinicians frequently misinterpret normal CRP as evidence against organic disease; in ME/CFS, normal CRP is part of the expected biomarker profile rather than a disconfirmatory finding
2 Cell Function Markers
2.1 NK Cell Activity
One of the most replicated findings:
- Reduced cytotoxic function in most studies
- 40–60% reduction compared to controls
- Correlates with severity in some studies
- Functional assay more informative than cell counts
2.2 T Cell Markers
Various abnormalities reported:
- Exhaustion markers (PD-1, Tim-3)
- Altered CD4/CD8 ratios (inconsistent direction)
- Reduced regulatory T cell function
- Th1/Th2 imbalance
2.3 B Cell Profiles
NIH study findings highlight B cell importance:
- Naïve/memory B cell ratio shift
- Chronic antigenic stimulation pattern
- Potential autoantibody-producing populations
2.4 IgG Subclass Panel
IgG subclass deficiency, particularly IgG3 deficiency, is found in a subset of ME/CFS patients and is clinically actionable: documented subclass deficiency can inform consideration of IVIG supplementation in refractory cases Testing includes IgG1–IgG4 quantification; IgG3 is the primary antiviral subclass and may reflect impaired antiviral immune responses.
3 Mast Cell Mediator Biomarkers
Mast cell activation is increasingly recognized as a comorbidity in ME/CFS (estimated 17–25% prevalence (Rohrhofer et al. 2025)), and mast cell mediators represent a distinct biomarker category with both diagnostic and mechanistic value. Standard serum tryptase—the traditional mast cell activation marker—has limited sensitivity in ME/CFS-relevant presentations: in a prospective POTS cohort (\(n = 69\)), Kohno et al. (Kohno et al. 2021) found tryptase elevated in only 9% of patients with mast cell activation, compared to 52% for histamine/methylhistamine and 36% for prostaglandin D2.
3.1 Urinary Mast Cell Mediator Panel
Urinary mediators offer the most practical approach for detecting mast cell activation in ME/CFS, particularly for energy-limited patients unable to reach a clinic during acute episodes (Voelker and Pongdee 2024). A paired baseline-to-acute measurement protocol provides superior diagnostic accuracy over absolute values (Voelker and Pongdee 2025):
- N-methylhistamine (NMH): Histamine metabolite; diagnostic ratio \(\geq\) 1.29 (acute/baseline). Collected via 24-hour or spot urine. Dietary histamine intake can cause \(\sim\) 30% elevation, requiring standardized collection conditions.
- Leukotriene E4 (LTE4): Shows greatest average acute elevation (\(\sim\) 36-fold in acute events); diagnostic ratio \(\geq\) 1.36. Not mast-cell-specific (also produced by eosinophils, basophils).
- 2,3-dinor-11\(\beta\)-PGF2\(\alpha\): Prostaglandin D2 metabolite; diagnostic ratio \(\geq\) 1.31; mean ratio \(\sim\) 7.28 in acute events. Maeda et al. (Maeda et al. 2017) demonstrated that urinary tetranor-PGDM is specifically elevated in food allergy patients (\(n = 9\)) versus other allergic diseases, suggesting relative specificity for intestinal mast cell activation—though this finding requires replication in non-IgE mast cell activation. The urinary collection window extends to 5 hours post-symptom onset (versus 1–4 hours for serum tryptase), and home collection eliminates the need for clinic visits during acute episodes. Random urine panels are commercially available through reference laboratories (Voelker and Pongdee 2024).
3.2 Application to Food-Triggered Mast Cell Activation
For ME/CFS patients with suspected food-triggered mast cell activation (see Section CD33+HLA-DR− MDSC Frequency as a Functional Readout of the HSAT2 Loop), paired urinary mediator testing during elimination-rechallenge protocols represents a potential diagnostic approach: collect baseline urine on a neutral day, then repeat collection 4–6 hours after a controlled food challenge. Elevated ratios in one or more mediators would support mast cell activation by the specific food. This protocol has not been prospectively validated in ME/CFS or MCAS populations, but the underlying mediator assays are clinically validated and the paired design controls for inter-individual variability (Voelker and Pongdee 2025).